Clinical Trial Update: Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating vedolizumab for prevention of intestinal acute graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation Complications

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Hematopoietic Stem Cells | Phase 3 | Status: COMPLETED | Results posted: 2023-04-14